title: Adult primary pure teratoma of the testis. The Indiana experience.
abstract: BACKGROUND
  Pure testicular teratoma in adults is a relatively rare malignant tumor with the ability to invade and metastasize. Pure teratoma generally is believed to be less aggressive and less likely to progress, to present in lower stages, and to have better survival rates then other forms of germ cell tumor. Consequently, clinical stage A patients with pure testicular teratoma commonly have been considered to be managed best by surveillance.
  
  
  METHODS
  A computerized database search identified 41 patients presenting to Indian University with pure teratoma in the orchiectomy specimen. These patients were further subdivided into four groups based on clinical stage, as follows: Group I, 18 patients with clinical Stage A disease; Group II, 4 patients with clinical Stages A-B1 disease based on questionable computed tomography findings; Group III, 3 patients with clinical Stage B1 disease; Group IV, 16 patients with advanced stage (B3-C) disease. The experience with these patients was reviewed.
  
  
  RESULTS
  The overall risk of lymph node metastasis in retroperitoneal lymph node dissection (RPLND) and the risk of relapse after RPLND for patients with low stage pure testicular teratoma (groups I-III) were 40 and 16%, respectively. In patients with clinical Stage A teratoma, the risk of retroperitoneal metastasis in RPLND was 16.7% and the relapse rate was 11.1%. In addition, nearly 37% of referred patients with pure teratoma presented with advanced disease.
  
  
  CONCLUSIONS
  These data provide additional confirmation of the metastatic potential of pure testicular teratoma. The proper management of the adult clinical stage A patient with primary pure teratoma of the testis should not necessarily differ from the management of any other histologic type of nonseminomatous testicular tumor. Accordingly, histologic diagnosis of pure teratoma should not mandate surveillance. Instead, patients must be given adequate information regarding management options, as are all other patients presenting with clinical Stage A nonseminoma.
authors.affiliation: Department of Urology, Indiana University School of Medicine, Indianapolis, USA.
authors.forename: I
authors.initials: I
authors.lastname: Leibovitch
authors.forename: R S
authors.initials: RS
authors.lastname: Foster
authors.forename: T M
authors.initials: TM
authors.lastname: Ulbright
authors.forename: J P
authors.initials: JP
authors.lastname: Donohue
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005500:Follow-Up Studies; D006801:Humans; D007196:Indiana / Q000453:epidemiology; D007256:Information Systems; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D009367:Neoplasm Staging; D009919:Orchiectomy; D012187:Retroperitoneal Space; D012307:Risk Factors; D015996:Survival Rate; D013724:Teratoma / Q000453:epidemiology* / Q000473:pathology / Q000556:secondary / Q000601:surgery; D013736:Testicular Neoplasms / Q000453:epidemiology* / Q000473:pathology / Q000601:surgery